Personalized medicine takes another step forward, as scientists from Pfizer and South Korea make progress developing a diagnostic test that can quickly and cheaply identify patients who can benefit from the company's lung cancer drug Xalkori (crizotinib).
E.U. regulators have recommended Pfizer's kidney cancer drug Inlyta be approved for use in patients who don't respond to other medications.
Xalkori was tested in children with rare cancers, and its success illustrates how targeted drugs can progress beyond their initial uses.
Cancer drug aficionados, rejoice. A slew of new studies goes public later today, as drugmakers gear up for next month's American Society of Clinical Oncology meeting.
Pfizer's ($PFE) new Xalkori cancer treatment becomes the poster child for pharma's post-mega-blockbuster strategy in a Wall Street Journal analysis of targeted treatments. Together with Roche and
Pfizer's ($PFE) Lipitor gap is beginning to fill in. The company won FDA approval for its targeted lung cancer drug Xalkori, which some analysts expect to add a very healthy $2.5 billion in peak...